NCT02068794 - MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 25, 2014

Primary Completion Date

March 15, 2024

Study Completion Date

December 1, 2025

Conditions

Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaMalignant Ovarian Brenner TumorOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaOvarian Transitional Cell CarcinomaOvarian Undifferentiated CarcinomaPrimary Peritoneal Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Mesenchymal Stem Cell Transplantation

Given IP

BIOLOGICAL

Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter

Given IP

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Chest Radiography

Undergo chest X-ray

PROCEDURE

Single Photon Tomography and Computed Tomography Scan

Undergo SPECT/CT

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester